Benitec Biopharma (BJ9) Price & Analysis

0 Followers

BJ9 Stock Chart & Stats

€3.06

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€3.06

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€3.06 - €3.06

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€283.26M

Enterprise Value€281.17M

Total Cash (Recent Filing)€179.97M

Total Debt (Recent Filing)€762.00K

Price to Earnings (P/E)―

BetaN/A

Next Earnings

Nov 16, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.98

Shares Outstanding34,882,725

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio2.05

Price to Book (P/B)3.52

Price to Sales (P/S)0.00

P/FCF Ratio-37.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€21.99

Price Target Upside618.47% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-1.04

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Expanded EquityMinimal leverage reduces pressure from debt service and preserves financial flexibility while the company advances its pipeline. The substantial increase in equity and assets provides a broader capital base to support operations, although ongoing losses remain a constraint.

Regulatory Path Advancing For BB-301A defined FDA review timeline and planned pivotal enrollment represent meaningful regulatory progress for the lead program. This can improve development planning and clarify the route toward potential commercialization, while additional data requirements keep execution risk material.

Focused DdRNAi Genetic-medicine PlatformA focused ddRNAi platform gives Benitec a consistent technological foundation across its therapeutic development activities. If successfully translated into approved medicines, gene silencing could support differentiated treatments and create value beyond a single development candidate.

Bears Say

No Meaningful Revenue TractionThe absence of meaningful revenue indicates that Benitec remains dependent on development-stage progress rather than an established commercial business. Until a program reaches commercialization, revenue visibility and operating leverage remain limited, increasing reliance on future milestones.

Widening Net LossesLosses are increasing in absolute terms as the company funds research and development without commercial revenue. Persistent negative operating profit reduces earnings quality and suggests that future value depends heavily on successful clinical development and eventual product approval.

Persistent Cash Burn And Funding DependenceSustained negative operating and free cash flow means reported losses are translating into real cash outflows. Even with some improvement in 2026, Benitec must continue funding operations externally until revenues materialize, creating ongoing capital dependence.

Benitec Biopharma News

Benitec Biopharma says BB-301 pivotal still on track for mid-2027

Benitec announced formal FDA feedback following a Type C meeting in Q3. Discussions on an open-label, single-arm pivotal...

8d ago

BNTC

Benitec Biopharma price target raised to $17 from $16 at Wedbush

Wedbush raised the firm’s price target on Benitec Biopharma (BNTC) to $17 from $16 and keeps an Outperform...

28d ago

BNTC

Benitec Biopharma price target raised to $17 from $16 at Wedbush

Wedbush analyst Yun Zhong raised the firm’s price target on Benitec Biopharma (BNTC) to $17 from $16 and...

28d ago

BNTC

Benitec Biopharma files $200M mixed securities shelf

17:11 EDT Benitec Biopharma (BNTC) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

29d ago

BNTC

BB-301 Momentum, Favorable FDA Feedback Support Buy Rating with Unchanged $32 Price Target

Benitec Biopharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

7d ago

BNTC

FDA Clarity on BB-301 Phase 3 Supports Buy Rating on BNTC; $17 Price Target Reiterated

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on Benitec Biopharma, with a...

8d ago

BNTC

Benitec advances BB-301 gene therapy after FDA feedback

Benitec Biopharma ( ($BNTC) ) has shared an update. On October 5, 2026, Benitec Biopharma reported that the...

8d ago

BNTC

BNTC: BB-301 Clinical Progress and Strong Cash Position Drive Ritu Baral’s Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating yesterday....

27d ago

BNTC

Wedbush bullish on Benitec Biopharma, initiates with an Outperform

As previously reported, Wedbush initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $16 price target...

3M ago

BNTC

Benitec Biopharma initiated with an Outperform at Wedbush

Wedbush initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $16 price target Published first on...

3M ago

BNTC

Guggenheim downgrades Benitec to Neutral, terminates coverage

Guggenheim downgraded Benitec Biopharma (BNTC) to Neutral from Buy without a price target while subsequently terminating coverage of...

4M ago

BNTC

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Debjit Chattopadhyay downgraded Benitec Biopharma (BNTC) to Neutral from Buy with no price target Published first...

4M ago

BNTC

Benitec Biopharma Announces Board Changes and New Director

Benitec Biopharma ( ($BNTC) ) has provided an update. On May 22, 2026, Benitec Biopharma Inc.’s board appointed...

5M ago

BNTC

Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Benitec Biopharma and keeping the price target...

5M ago

BNTC

BJ9 FAQ

What was Benitec Biopharma Ltd’s price range in the past 12 months?

Benitec Biopharma Ltd lowest stock price was €3.06 and its highest was €3.06 in the past 12 months.

What is Benitec Biopharma Ltd’s market cap?

Benitec Biopharma Ltd’s market cap is €283.26M.

When is Benitec Biopharma Ltd’s upcoming earnings report date?

Benitec Biopharma Ltd’s upcoming earnings report date is Nov 16, 2026 which is in 34 days.

How were Benitec Biopharma Ltd’s earnings last quarter?

Benitec Biopharma Ltd released its earnings results on Sep 14, 2026. The company reported -€0.233 earnings per share for the quarter, beating the consensus estimate of -€0.236 by €0.004.

Is Benitec Biopharma Ltd overvalued?

According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Benitec Biopharma Ltd pay dividends?

Benitec Biopharma Ltd does not currently pay dividends.

What is Benitec Biopharma Ltd’s EPS estimate?

Benitec Biopharma Ltd’s EPS estimate is -0.24.

How many shares outstanding does Benitec Biopharma Ltd have?

Benitec Biopharma Ltd has 34,882,725 shares outstanding.

What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?

Benitec Biopharma Ltd reported an EPS of -€0.233 in its last earnings report, beating expectations of -€0.236. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Benitec Biopharma Ltd?

Currently, no hedge funds are holding shares in DE:BJ9

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Benitec Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-28.41%

Trailing 12-Months

Asset Growth

83.37%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Benitec Biopharma Ltd

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Benitec Biopharma (BJ9) Earnings & Revenues

Historic Earnings Reports

BJ9 Stock 12 Month Forecast

Average Price Target

€21.99

▲(618.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","29":"€29","8.75":"€8.75","15.5":"€15.5","22.25":"€22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.52128704,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€28.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.98515876,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€21.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.15193374,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,5.018560541538462,6.9771210830769235,8.935681624615386,10.894242166153846,12.852802707692309,14.811363249230771,16.76992379076923,18.728484332307694,20.687044873846155,22.645605415384615,24.604165956923076,26.56272649846154,{"y":28.52128704,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.515781443076923,5.971562886153846,7.42734432923077,8.883125772307693,10.338907215384616,11.79468865846154,13.250470101538463,14.706251544615386,16.162032987692307,17.61781443076923,19.073595873846152,20.529377316923078,{"y":21.98515876,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.9901487492307695,4.920297498461538,5.850446247692307,6.780594996923076,7.710743746153845,8.640892495384616,9.571041244615385,10.501189993846154,11.431338743076923,12.361487492307692,13.29163624153846,14.221784990769232,{"y":15.15193374,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >